Taking migraine seriously

About one in seven people lives with what's ranked as the second-most debilitating disease on the planet, but experts say research into its causes and treatments is dramatically underfunded.
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news

Related Links:

Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that could help it fend off competition from Eli Lilly and Co in the market for migraine drugs.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Condition:   Post-Dural Puncture Headache Interventions:   Drug: Dexmedetomidine Nebulization;   Other: 0.9% Saline Nebulization Sponsor:   Zagazig University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study investigated differences between episodic and chronic cluster headache with a focus on family history, traumatic history, and change in phenotype. Do these factors differ between subtypes?Headache
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
A 43 ‐year‐old man who was treated with interferon‐beta for multiple sclerosis was presented with hypertension, headache, nausea/vomiting, blurred vision, and renal dysfunction. The treatment with drugs and dialysis relieved the symptoms. Despite plasmapheresis is known to cause improvement in rena l function, no such improvement was seen in patient. AbstractA 43 ‐year‐old man who was treated with interferon‐beta for multiple sclerosis was presented with hypertension, headache, nausea/vomiting, blurred vision, and renal dysfunction. The treatment with drugs and dialysis relieved the symptoms. Despite plasmapher...
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
AbstractEptinezumab is a humanized mAb that targets calcitonin gene ‐related peptide and is under regulatory review for the prevention of episodic and chronic migraine (EM, CM). It is important to determine whether exposures achieved with intravenous (IV) administration of eptinezumab achieve desired pharmacologic effects. Population pharmacokinetics, including do se‐ and exposure‐response analyses, were performed using patient‐level data from the eptinezumab clinical trial program with IV doses ranging from 10 to 1000 mg in pharmacokinetic analyses or 10 to 300 mg in phase 2/3 clinical studies in patient...
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conclusion Surgical decompression of the optic canal and orbital contents for tumor related sphenoid wing hyperostosis should be strongly considered, despite an extended duration of visual change and loss. This case report shows that vision can be significantly restored even after symptoms have been present for greater than 6 months. [...] Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text
Source: Journal of Neurological Surgery Reports - Category: Neurosurgery Authors: Tags: Case Report Source Type: research
ConclusionWe concluded that SWI can detect CMBs in patients with IIH especially in   patients with higher GRS for headache.
Source: Japanese Journal of Radiology - Category: Radiology Source Type: research
On her run, she finished a six-mile loop with no trouble, but she felt a little off: a bit of chest tightness, a headache. Was this coronavirus?
Source: NYT Health - Category: Consumer Health News Authors: Tags: Coronavirus (2019-nCoV) Tests (Medical) Hospitals Coughs Doctors United States Source Type: news
(HAMBURG, Pa.) — The spring breezes of 2020 are carrying more than just tree pollen. There’s a whiff of paranoia in the air. For millions of seasonal allergy sufferers, the annual onset of watery eyes and scratchy throats is bumping up against the global spread of a new virus that produces its own constellation of respiratory symptoms. Forecasters are predicting a brutal spring allergy season for swaths of the U.S. at the same time that COVID-19 cases are rising dramatically. That’s causing angst for people who never have had to particularly worry about their hay fever, other than to stock up on antihista...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 News Desk wire Source Type: news
Bright Machines, a smart manufacturing company based in San Francisco, offers automation solutions for assembly and inspection of dozens of products, including for the medical device industry. Medgadget recently featured an interview with Jesse Lehga...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Public Health Source Type: blogs
More News: Headache | Health | Migraine